Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2019

View Archived Issues

Glial alpha-synuclein causes neuronal toxicity

Decoy platelets for thrombosis, metastasis

How microbiome cell toxin damages host cell DNA

MAPK4 blockade inhibits AKT/mTOR pathway and shows promise for cancer therapy

Fatty acid transporter CD36 inhibition could be beneficial in prostate cancer

Allakos presents results from phase I study of AK-002 in indolent systemic mastocytosis

First patient dosed in phase II study of NYX-783

Gamida Cell and Editas Medicine to study CRISPR editing of NAM-NK cells

Funding continues for Aravive's anti-GAS6 fusion protein development

Discovery and characterization of novel PROTAC AR degrader, ARD-69

First-in-human results presented for SynGEM vaccine

GlaxoSmithKline Intellectual Property divulges PI3K inhibitors

Merck & Co. describes new IDO1 inhibitors

Inosine supplementation and modulation of adenosine deaminase as a potential therapy against ALS

Jazz Pharmaceuticals identifies compounds for sleep disorders

Vical discontinues phase II trial of VL-2397 as it pursues strategic alternative review process

Search for alternative Notch 1 pathway modulators leads Novartis to NVS-ZP7-4

Semma Therapeutics divulges new compositions for diabetes

GlaxoSmithKline Biologicals patents adenoviral vectors for CHIKV infections

AlzProtect completes phase I food effect study with AZP-2006

FDA approves Esperoct for hemophilia A

EZH2 inhibitors may be a means of treating scleroderma

Catabasis reports growth data from phase II trial of edasalonexent for Duchenne muscular dystrophy

ReNeuron reports vision improvement in first phase II cohort with hRPC cell therapy for RP

FDA places partial clinical hold on phase I study of XmAb-14045

Phase II trial of VAL-083 in newly diagnosed GBM achieves halfway enrollment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...